This indicates that relatively lower CEACAM6 expression levels before chemotherapy are associated with achieving pCR following NAC, supporting its potential as both a predictive and therapeutic biomarker for the efficacy of neoadjuvant treatment in breast cancer. Here, CEACAM6 is linked to breast cancer.